Featured Story | By Nick Paul Taylor GlaxoSmithKline is planning to sell more than one-third of its 92-acre R&D site in Stevenage, U.K. The proposed sale, which comes amid criticism of GSK’s historically low R&D investment, is part of a plan to turn part of the site into a life science campus. read more |
| |
|---|
|
Top Stories By Amirah Al Idrus Months after finally revealing its first weapons against cancer, Erasca has pulled off a $300 million IPO. The proceeds will propel an SHP2 inhibitor and an ERK inhibitor through the clinic and get at least one more prospect into human trials. read more By Kyle LaHucik AbbVie's Allergan Aesthetics unit, famous for Botox, is among the investors pouring $15 million into Stemson Therapeutics, which sees itself a first mover in attempting to "reprogram cells to become hair-producing cells." read more Sponsored by: Patheon by Thermo Fisher Scientific Choose the right AAV platform for your viral vector-based gene therapy. read more By Nick Paul Taylor Polyphor is closing its failed phase 3 breast cancer clinical trial and planning to lay off staff to lower its costs. The Swiss biotech said its “initial” restructuring will affect 29 positions and it is continuing a strategic assessment. read more By Annalee Armstrong GlaxoSmithKline has revealed that a phase 3 anemia drug improved and maintained hemoglobin levels in patients—a day after FibroGen’s competing drug was roasted at an FDA advisory panel meeting. The U.K. pharmaceutical giant has been working on the Ascend program for years, with 8,000 patients enrolled and treated for up to 3.75 years. So, bold timing indeed to see the new results released after a competitor failed to clear a crucial regulatory hurdle. read more By Fraiser Kansteiner Regeneron laid plans for a six-year, $1.8 billion expansion at its existing Westchester County campus, according to the New York Governor’s office. The expansion will see the company grow its New York headcount by 1,000 over the next five years. read more By Kyle LaHucik French pharma Ipsen is dishing out $28 million upfront to IRLAB with $335 million in potential biobucks to nab a midstage Parkinson's disease therapy, digging deeper into the difficult brain disorder. Mesdopetam is currently in a phase 2b trial, which will be completed by IRLAB. read more By Noah Higgins-Dunn In a stinging rebuke against Biogen's Alzheimer's drug Aduhelm, a group of independent experts with U.S. cost watchdog ICER issued a 15-to-0 vote against the treatment. Biogen brought its own set of arguments to the meeting but was unable to convince the group. read more By Andrea Park HeartFlow will merge with Longview Acquisition Corp. II., a special purpose acquisition company that made its own public debut earlier this year. Once the merger is complete, the resulting public company will operate under HeartFlow's banner, with the NYSE ticker “HFLO.” read more By Kevin Dunleavy Sinovac and Sinopharm will supply up to 500 million vaccine doses to the COVAX worldwide relief effort. Seagen-Astellas gained two FDA approvals for bladder cancer treatment Padcev. BGI Group and the Chinese military reportedly shared data on millions of pregnant women who have used BGI's genetic test. And more. read more By Kyle LaHucik Anticancer Bioscience hired Hong Liu as vice president of clinical development, similar to his VP role at Eureka Therapeutics overseeing R&D. Eric Walk, M.D., is venturing on a new path, leaving Roche Tissue Diagnostics to be PathAI's chief medical officer. Tessera Therapeutics extended its leadership hiring binge with president and chief financial officer Howard Liang, Ph.D. read more Resources Sponsored by: WCG Engage Independent Expert Endpoint Adjudication and Data Monitoring Committees in a strategic manner to identify methods for retrospective and prospective evaluations that may improve competitive advantage and bolster regulatory submissions. Sponsored by: Patheon by Thermo Fisher Scientific Take a closer look at your supply chain to ensure it delivers with speed, efficiency, and quality — all within budget. Sponsored by: PA Consulting What does the future of Cell & Gene Therapy look like? Sponsored by: Patheon by Thermo Fisher Scientific Choose the right AAV platform for your viral vector-based therapy Sponsored by: Blue Matter Consulting E-book to get newcomers “up to speed” quickly on digital health and digital therapeutics while also addressing key issues important to those already familiar with the topic. Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process intesification Sponsored By: Remarque Systems Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. | 
